Paloma Partners’s Pacira BioSciences PCRX Stock Holding History

Paloma Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,151	Closed	-$209K	–	1418
2024 Q1	$209K	Buy	+7,151	New	+$220K	0.01%	597
2020 Q4	–	Sell	-4,512	Closed	-$271K	–	2092
2020 Q3	$271K	Buy	4,512 +324	+8%	+$18.8K	0.01%	1554
2020 Q2	$220K	Buy	+4,188	New	+$175K	﹤0.01%	1639
2019 Q2	–	Sell	-5,752	Closed	-$219K	–	2080
2019 Q1	$219K	Buy	+5,752	New	+$224K	0.01%	1470
2018 Q1	–	Sell	-9,903	Closed	-$452K	–	2195
2017 Q4	$452K	Buy	+9,903	New	+$392K	0.01%	1371
2017 Q1	–	Sell	-8,023	Closed	-$259K	–	2170
2016 Q4	$259K	Buy	+8,023	New	+$268K	﹤0.01%	1751
2016 Q3	–	Sell	-13,944	Closed	-$470K	–	2056
2016 Q2	$470K	Buy	+13,944	New	+$685K	0.01%	1563

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paloma Partners's PCRX Position: Q2 2024 in Review

Paloma Partners sold out of Pacira BioSciences (PCRX) in Q2 2024, closing a stake of 7,151 shares — an estimated $209K sold.

Paloma Partners first reported a position in PCRX in Q2 2016 and held it in 7 quarters. The position peaked at $470K in Q2 2016. 282 funds tracked by Wall St. Rank hold PCRX as of Q2 2024.

Paloma Partners reported no remaining Pacira BioSciences position as of Q2 2024 after selling out during the quarter.
Paloma Partners sold 7,151 Pacira BioSciences shares in Q2 2024, an estimated $209K.
Paloma Partners first reported a position in Pacira BioSciences in Q2 2016 and held it in 7 quarters.
Paloma Partners's Pacira BioSciences position peaked at $470K in Q2 2016.
282 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2024.

Based on Paloma Partners's 13F filing for Q2 2024, filed 14 Aug 2024.